Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

PURPOSE: To determine the efficacy and toxicity of the combination of sorafenib, cytarabine, and idarubicin in patients with acute myeloid leukemia (AML) younger than age 65 years. PATIENTS AND METHODS: In the phase I part of the study, 10 patients with relapsed AML were treated with escalating dose...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Ravandi, Farhad, Cortes, Jorge E., Jones, Daniel, Faderl, Stefan, Garcia-Manero, Guillermo, Konopleva, Marina Y., O'Brien, Susan, Estrov, Zeev, Borthakur, Gautam, Thomas, Deborah, Pierce, Sherry R., Brandt, Mark, Byrd, Anna, Bekele, B. Nebiyou, Pratz, Keith, Luthra, Rajyalakshmi, Levis, Mark, Andreeff, Michael, Kantarjian, Hagop M.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2010
Onderwerpen:
Original Reports
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2930809/
https://ncbi.nlm.nih.gov/pubmed/20212254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.4888
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items